Necrotizing Enterocolitis Market - A Global and Regional Analysis: Focus on Treatment Type, Diagnosis, End User, Country, and Region - Analysis and Forecast, 2025-2035
Description
Global Necrotizing Enterocolitis Market, Analysis and Forecast: 2025-2035
Necrotizing enterocolitis (NEC) is a serious gastrointestinal disease that primarily affects premature or critically ill newborns, especially those with very low birth weight. It involves inflammation and injury of the intestinal lining, which can progress to tissue death (necrosis) and, in severe cases, perforation of the intestine. The exact cause of NEC is not fully understood, but it is thought to result from a combination of factors such as immature gut development, reduced blood flow to the intestines, and abnormal bacterial colonization.
Infants with NEC may present with symptoms like abdominal swelling, feeding intolerance, bloody stools, lethargy, and instability in vital signs. The condition can progress rapidly, making early diagnosis and intervention critical. Treatment typically includes bowel rest, antibiotic therapy, and supportive care, while severe cases may require surgical removal of damaged portions of the intestine. Despite advances in neonatal care, NEC remains a leading cause of morbidity and mortality in preterm infants, driving the need for better preventive and therapeutic strategies.
The global necrotizing enterocolitis market is being propelled by several key drivers, foremost among them the rising incidence of premature births and low-birth-weight infants, which significantly increases vulnerability to NEC and necessitates advanced preventive and therapeutic interventions. This is complemented by the increasing availability of specialized nutritional formulas and human milk-based products, designed to support the unique digestive and immune needs of preterm infants while reducing NEC risk. Furthermore, continuous advancements in Neonatal Intensive Care Unit (NICU) infrastructure and technology—ranging from improved monitoring systems and diagnostic imaging to precision feeding devices—are enhancing early detection, personalized treatment, and overall survival rates, thereby expanding the scope and demand for NEC-focused solution.
The global necrotizing enterocolitis (NEC) market faces significant challenges that continue to hinder optimal outcomes for affected infants. Despite advancements in treatment, NEC remains associated with high mortality and morbidity rates, particularly among extremely premature and low-birth-weight infants, creating an urgent unmet medical need. Early detection is further complicated by the limited availability of definitive diagnostic biomarkers, often resulting in delayed intervention and increased disease severity. Additionally, the industry contends with mounting legal and regulatory pressures surrounding infant formula safety, with high-profile litigations and evolving compliance requirements placing both reputational and financial strain on manufacturers and healthcare providers.
The global necrotizing enterocolitis (NEC) market is experiencing steady growth, driven by the rising need for effective interventions to prevent disease onset, manage acute symptoms, reduce complications, and improve survival outcomes in premature and low-birth-weight infants. Key therapeutic approaches include human milk-based nutritional products to support gut health, probiotic and microbiome-targeted therapies to restore intestinal balance, and surgical interventions such as bowel resection or peritoneal drainage for severe cases. Recent advancements have introduced novel live biotherapeutic products, immunomodulators, and biomarker-guided diagnostics, offering more targeted, preventive, and safer treatment strategies. Leading healthcare and biotechnology companies are investing in next-generation nutrition solutions, microbiome therapeutics, and innovative diagnostic tools to enhance early detection and improve efficacy while minimizing treatment-related risks. Precision medicine initiatives, supported by genomic profiling and microbiome analysis, are enabling more personalized interventions tailored to an infant’s specific risk profile. Furthermore, growing awareness among neonatologists, improvements in neonatal intensive care unit (NICU) technology, and expanding access to advanced nutritional and therapeutic solutions in emerging markets are further propelling market growth, positioning NEC management for significant clinical and technological advancements in the coming years.
The global necrotizing enterocolitis (NEC) market presents substantial opportunities driven by innovation and expanding healthcare access. The growing adoption of human milk-based nutrition and probiotic therapies offers promising preventive strategies, as these approaches have shown potential in reducing NEC incidence and improving gut health in preterm infants. Increasing research and development investments in microbiome modulation, immunotherapy, and novel biologics are opening new avenues for targeted interventions that address the disease at its root causes. Moreover, the expansion of neonatal care facilities in emerging markets, supported by improving healthcare infrastructure and government initiatives, is creating fertile ground for the introduction of advanced NEC diagnostics, therapeutics, and nutritional solutions to underserved populations.
Market Segmentation:
Segmentation 1: by Treatment Type
Medical Management
Antibiotic Therapy
Probiotics & Prebiotics
Others
Surgical Intervention
Peritoneal Drainage
Laparotomy & Resection
Stoma Formation
Adjunctive & Supportive Therapies
Immunotherapies
Growth Factors & Cytoprotective Agents
Segmentation 2: by Diagnosis
Imaging Techniques
Abdominal X-Ray
Abdominal Ultrasound (AUS)
Doppler Ultrasound
Laboratory Tests
Complete Blood Count (CBC)
C-Reactive Protein (CRP) & Other Inflammatory Markers
Others
Stool Tests
Segmentation 3: by End User
Hospitals & NICUs
Paediatric Clinics
Academic & Research Institutes
Others
Segmentation 4: by Region
North America
Europe
Asia-Pacific
The global necrotizing enterocolitis (NEC) market is witnessing notable trends that are reshaping prevention, diagnosis, and treatment approaches. One key trend is the adoption of AI-powered imaging and predictive analytics, enabling earlier and more accurate detection of NEC risk through advanced interpretation of neonatal scans and patient data. There is also a growing shift toward preventive strategies using live biotherapeutic products, including targeted probiotics and microbiome-modulating agents, aimed at strengthening intestinal health before the onset of disease. Additionally, collaborative research initiatives between hospitals, academic institutions, and industry players are accelerating the translation of laboratory findings into clinically viable solutions, fostering innovation and expanding the pipeline of NEC-specific interventions.
*PDF email from publisher allows for 1-3 users, with permission to print*
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Necrotizing enterocolitis (NEC) is a serious gastrointestinal disease that primarily affects premature or critically ill newborns, especially those with very low birth weight. It involves inflammation and injury of the intestinal lining, which can progress to tissue death (necrosis) and, in severe cases, perforation of the intestine. The exact cause of NEC is not fully understood, but it is thought to result from a combination of factors such as immature gut development, reduced blood flow to the intestines, and abnormal bacterial colonization.
Infants with NEC may present with symptoms like abdominal swelling, feeding intolerance, bloody stools, lethargy, and instability in vital signs. The condition can progress rapidly, making early diagnosis and intervention critical. Treatment typically includes bowel rest, antibiotic therapy, and supportive care, while severe cases may require surgical removal of damaged portions of the intestine. Despite advances in neonatal care, NEC remains a leading cause of morbidity and mortality in preterm infants, driving the need for better preventive and therapeutic strategies.
The global necrotizing enterocolitis market is being propelled by several key drivers, foremost among them the rising incidence of premature births and low-birth-weight infants, which significantly increases vulnerability to NEC and necessitates advanced preventive and therapeutic interventions. This is complemented by the increasing availability of specialized nutritional formulas and human milk-based products, designed to support the unique digestive and immune needs of preterm infants while reducing NEC risk. Furthermore, continuous advancements in Neonatal Intensive Care Unit (NICU) infrastructure and technology—ranging from improved monitoring systems and diagnostic imaging to precision feeding devices—are enhancing early detection, personalized treatment, and overall survival rates, thereby expanding the scope and demand for NEC-focused solution.
The global necrotizing enterocolitis (NEC) market faces significant challenges that continue to hinder optimal outcomes for affected infants. Despite advancements in treatment, NEC remains associated with high mortality and morbidity rates, particularly among extremely premature and low-birth-weight infants, creating an urgent unmet medical need. Early detection is further complicated by the limited availability of definitive diagnostic biomarkers, often resulting in delayed intervention and increased disease severity. Additionally, the industry contends with mounting legal and regulatory pressures surrounding infant formula safety, with high-profile litigations and evolving compliance requirements placing both reputational and financial strain on manufacturers and healthcare providers.
The global necrotizing enterocolitis (NEC) market is experiencing steady growth, driven by the rising need for effective interventions to prevent disease onset, manage acute symptoms, reduce complications, and improve survival outcomes in premature and low-birth-weight infants. Key therapeutic approaches include human milk-based nutritional products to support gut health, probiotic and microbiome-targeted therapies to restore intestinal balance, and surgical interventions such as bowel resection or peritoneal drainage for severe cases. Recent advancements have introduced novel live biotherapeutic products, immunomodulators, and biomarker-guided diagnostics, offering more targeted, preventive, and safer treatment strategies. Leading healthcare and biotechnology companies are investing in next-generation nutrition solutions, microbiome therapeutics, and innovative diagnostic tools to enhance early detection and improve efficacy while minimizing treatment-related risks. Precision medicine initiatives, supported by genomic profiling and microbiome analysis, are enabling more personalized interventions tailored to an infant’s specific risk profile. Furthermore, growing awareness among neonatologists, improvements in neonatal intensive care unit (NICU) technology, and expanding access to advanced nutritional and therapeutic solutions in emerging markets are further propelling market growth, positioning NEC management for significant clinical and technological advancements in the coming years.
The global necrotizing enterocolitis (NEC) market presents substantial opportunities driven by innovation and expanding healthcare access. The growing adoption of human milk-based nutrition and probiotic therapies offers promising preventive strategies, as these approaches have shown potential in reducing NEC incidence and improving gut health in preterm infants. Increasing research and development investments in microbiome modulation, immunotherapy, and novel biologics are opening new avenues for targeted interventions that address the disease at its root causes. Moreover, the expansion of neonatal care facilities in emerging markets, supported by improving healthcare infrastructure and government initiatives, is creating fertile ground for the introduction of advanced NEC diagnostics, therapeutics, and nutritional solutions to underserved populations.
Market Segmentation:
Segmentation 1: by Treatment Type
Medical Management
Antibiotic Therapy
Probiotics & Prebiotics
Others
Surgical Intervention
Peritoneal Drainage
Laparotomy & Resection
Stoma Formation
Adjunctive & Supportive Therapies
Immunotherapies
Growth Factors & Cytoprotective Agents
Segmentation 2: by Diagnosis
Imaging Techniques
Abdominal X-Ray
Abdominal Ultrasound (AUS)
Doppler Ultrasound
Laboratory Tests
Complete Blood Count (CBC)
C-Reactive Protein (CRP) & Other Inflammatory Markers
Others
Stool Tests
Segmentation 3: by End User
Hospitals & NICUs
Paediatric Clinics
Academic & Research Institutes
Others
Segmentation 4: by Region
North America
Europe
Asia-Pacific
The global necrotizing enterocolitis (NEC) market is witnessing notable trends that are reshaping prevention, diagnosis, and treatment approaches. One key trend is the adoption of AI-powered imaging and predictive analytics, enabling earlier and more accurate detection of NEC risk through advanced interpretation of neonatal scans and patient data. There is also a growing shift toward preventive strategies using live biotherapeutic products, including targeted probiotics and microbiome-modulating agents, aimed at strengthening intestinal health before the onset of disease. Additionally, collaborative research initiatives between hospitals, academic institutions, and industry players are accelerating the translation of laboratory findings into clinically viable solutions, fostering innovation and expanding the pipeline of NEC-specific interventions.
*PDF email from publisher allows for 1-3 users, with permission to print*
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
- Executive Summary
- Scope of Study
- Market/Product Definition
- Inclusion and Exclusion Criteria
- Key Questions Answered
- Analysis and Forecast Note
- 1. Global Necrotizing Enterocolitis Market: Industry Outlook
- 1.1 Market Overview
- 1.2 Market Trends
- 1.3 Regulatory Landscape / Compliance
- 1.3.1 U.S.
- 1.3.2 Germany
- 1.3.3 U.K.
- 1.3.4 China
- 1.3.5 Japan
- 1.3.6 Rest-of-the-World
- 1.4 Pricing Analysis
- 1.5 Market Dynamics
- 1.5.1 Market Drivers
- 1.5.1.1 Impact Analysis
- 1.5.2 Market Restraints
- 1.5.2.1 Impact Analysis
- 1.5.3 Market Opportunities
- 2. Global Necrotizing Enterocolitis Market (by Treatment Type), $Million, 2024-2035
- 2.1 Medical Management
- 2.1.1 Antibiotic Therapy
- 2.1.2 Probiotics & Prebiotics
- 2.1.3 Others
- 2.2 Surgical Intervention
- 2.2.1 Peritoneal Drainage
- 2.2.2 Laparotomy & Resection
- 2.2.3 Stoma Formation
- 2.3 Adjunctive & Supportive Therapies
- 2.3.1 Immunotherapies
- 2.3.2 Growth Factors & Cytoprotective Agents
- 2.3.3 Emerging Pharmacological Agents
- 3. Global Necrotizing Enterocolitis Market (by Diagnosis), $Million, 2024-2035
- 3.1 Imaging Techniques
- 3.1.1 Abdominal X-Ray
- 3.1.2 Abdominal Ultrasound (AUS)
- 3.1.3 Doppler Ultrasound
- 3.2 Laboratory Tests
- 3.2.1 Complete Blood Count (CBC)
- 3.2.2 C-Reactive Protein (CRP) & Other Inflammatory Markers
- 3.2.3 Blood Cultures
- 3.2.4 Serum Lactate Levels
- 3.3 Stool Tests
- 3.3.1 Occult Blood Test
- 3.3.2 Fecal Calprotectin
- 4. Global Necrotizing Enterocolitis Market (by End User), $Million, 2024-2035
- 4.1 Hospitals & NICUs
- 4.2 Pediatric Clinics
- 4.3 Academic & Research Institutes
- 4.4 Others
- 5. Global Necrotizing Enterocolitis Market (by Region), $Million, 2024-2035
- 5.1 North America
- 5.1.1 Key Findings
- 5.1.2 Market Dynamics
- 5.1.3 Market Sizing and Forecast
- 5.1.3.1 North America Necrotizing Enterocolitis Market, by Country
- 5.1.3.1.1 U.S.
- 5.1.3.1.1.1 Market Dynamics
- 5.1.3.1.1.2 Market Sizing and Forecast
- 5.1.3.1.2 Canada
- 5.1.3.1.2.1 Market Dynamics
- 5.1.3.1.2.2 Market Sizing and Forecast
- 5.2 Europe
- 5.2.1 Key Findings
- 5.2.2 Market Dynamics
- 5.2.3 Market Sizing and Forecast
- 5.2.3.1 Europe Necrotizing Enterocolitis Market, by Country
- 5.2.3.1.1 Germany
- 5.2.3.1.1.1 Market Dynamics
- 5.2.3.1.1.2 Market Sizing and Forecast
- 5.2.3.1.2 U.K.
- 5.2.3.1.2.1 Market Dynamics
- 5.2.3.1.2.2 Market Sizing and Forecast
- 5.2.3.1.3 France
- 5.2.3.1.3.1 Market Dynamics
- 5.2.3.1.3.2 Market Sizing and Forecast
- 5.2.3.1.4 Italy
- 5.2.3.1.4.1 Market Dynamics
- 5.2.3.1.4.2 Market Sizing and Forecast
- 5.2.3.1.5 Spain
- 5.2.3.1.5.1 Market Dynamics
- 5.2.3.1.5.2 Market Sizing and Forecast
- 5.2.3.1.6 Rest-of-Europe
- 5.2.3.1.6.1 Market Dynamics
- 5.2.3.1.6.2 Market Sizing and Forecast
- 5.3 Asia Pacific
- 5.3.1 Key Findings
- 5.3.2 Market Dynamics
- 5.3.3 Market Sizing and Forecast
- 5.3.3.1 Asia Pacific Necrotizing Enterocolitis Market, by Country
- 5.3.3.1.1 China
- 5.3.3.1.1.1 Market Dynamics
- 5.3.3.1.1.2 Market Sizing and Forecast
- 5.3.3.1.2 Japan
- 5.3.3.1.2.1 Market Dynamics
- 5.3.3.1.2.2 Market Sizing and Forecast
- 5.3.3.1.3 India
- 5.3.3.1.3.1 Market Dynamics
- 5.3.3.1.3.2 Market Sizing and Forecast
- 5.3.3.1.4 South Korea
- 5.3.3.1.4.1 Market Dynamics
- 5.3.3.1.4.2 Market Sizing and Forecast
- 5.3.3.1.5 Australia
- 5.3.3.1.5.1 Market Dynamics
- 5.3.3.1.5.2 Market Sizing and Forecast
- 5.3.3.1.6 Rest-of- Asia Pacific
- 5.3.3.1.6.1 Market Dynamics
- 5.3.3.1.6.2 Market Sizing and Forecast
- 5.4 Latin America
- 5.4.1 Key Findings
- 5.4.2 Market Dynamics
- 5.4.3 Market Sizing and Forecast
- 5.4.3.1 Latin America Necrotizing Enterocolitis Market, by Country
- 5.4.3.1.1 Brazil
- 5.4.3.1.1.1 Market Dynamics
- 5.4.3.1.1.2 Market Sizing and Forecast
- 5.4.3.1.2 Mexico
- 5.4.3.1.2.1 Market Dynamics
- 5.4.3.1.2.2 Market Sizing and Forecast
- 5.4.3.1.3 Rest of Latin America
- 5.4.3.1.3.1 Market Dynamics
- 5.4.3.1.3.2 Market Sizing and Forecast
- 5.5 Middle East and Africa
- 5.5.1 Key Findings
- 5.5.2 Market Dynamics
- 5.5.3 Market Sizing and Forecast
- 6. Necrotizing Enterocolitis Market - Competitive Benchmarking and Company Profiles
- 6.1 Key Strategies and Developments by Company
- 6.1.1 Funding Activities
- 6.1.2 Mergers and Acquisitions
- 6.1.3 Regulatory Approvals and Product Launches
- 6.1.4 Partnerships, Collaborations and Business Expansions
- 6.2 Company Profiles
- 6.2.1 Abbott Laboratories
- 6.2.1.1 Company Overview
- 6.2.1.2 Product Portfolio
- 6.2.1.3 Target Customers/End Users
- 6.2.1.4 Analyst View
- 6.2.2 Johnson & Johnson
- 6.2.2.1 Company Overview
- 6.2.2.2 Product Portfolio
- 6.2.2.3 Target Customers/End Users
- 6.2.2.4 Analyst View
- 6.2.3 Nestlé
- 6.2.3.1 Company Overview
- 6.2.3.2 Product Portfolio
- 6.2.3.3 Target Customers/End Users
- 6.2.3.4 Analyst View
- 6.2.4 Prolacta BioScience
- 6.2.4.1 Company Overview
- 6.2.4.2 Product Portfolio
- 6.2.4.3 Target Customers/End Users
- 6.2.4.4 Analyst View
- 6.2.5 Baxter International
- 6.2.5.1 Company Overview
- 6.2.5.2 Product Portfolio
- 6.2.5.3 Target Customers/End Users
- 6.2.5.4 Analyst View
- 6.2.6 Fresenius Kabi
- 6.2.6.1 Company Overview
- 6.2.6.2 Product Portfolio
- 6.2.6.3 Target Customers/End Users
- 6.2.6.4 Analyst View
- 6.2.7 Philips Healthcare
- 6.2.7.1 Company Overview
- 6.2.7.2 Product Portfolio
- 6.2.7.3 Target Customers/End Users
- 6.2.7.4 Analyst View
- 6.2.8 Evolve Biosystems
- 6.2.8.1 Company Overview
- 6.2.8.2 Product Portfolio
- 6.2.8.3 Target Customers/End Users
- 6.2.8.4 Analyst View
- 6.2.9 Infant Bacterial Therapeutics
- 6.2.9.1 Company Overview
- 6.2.9.2 Product Portfolio
- 6.2.9.3 Target Customers/End Users
- 6.2.9.4 Analyst View
- 6.2.10 B. Braun
- 6.2.10.1 Company Overview
- 6.2.10.2 Product Portfolio
- 6.2.10.3 Target Customers/End Users
- 6.2.10.4 Analyst View
- 6.2.11 Other Companies
- 7. Research Methodology
- List of Figures
- Figure: Necrotizing Enterocolitis Market (by Scenario), $Million, 2024, and 2035
- Figure: Global Necrotizing Enterocolitis Market, 2024 and 2035
- Figure: Global Necrotizing Enterocolitis Market Key Trends, Analysis
- Figure: North America Necrotizing Enterocolitis Market, $Million, 2024-2035
- Figure: Europe Necrotizing Enterocolitis Market, $Million, 2024-2035
- Figure: Asia-Pacific Necrotizing Enterocolitis Market, $Million, 2024-2035
- List of Tables
- Table: Market Snapshot
- Table: Global Necrotizing Enterocolitis Market Dynamics, Impact Analysis
- Table: Global Necrotizing Enterocolitis Market (by Region), $Million, 2024-2035
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.